Exploring the impact of acute viral exposure on clinical characteristics and antibody profiles in antiphospholipid syndrome: a study in CAPSTONE.
Antiphospholipid antibody
Antiphospholipid syndrome
SARS-CoV-2
Thrombocytopenia
Journal
Clinical and experimental medicine
ISSN: 1591-9528
Titre abrégé: Clin Exp Med
Pays: Italy
ID NLM: 100973405
Informations de publication
Date de publication:
18 Jun 2024
18 Jun 2024
Historique:
received:
23
04
2024
accepted:
10
06
2024
medline:
18
6
2024
pubmed:
18
6
2024
entrez:
18
6
2024
Statut:
epublish
Résumé
The relationship between antiphospholipid syndrome (APS) and acute viral infection, such as SARS-CoV-2, is unclear. This study aims to assess symptoms, antiphospholipid antibody (aPL) fluctuations, and complication risks in APS patients infected with SARS-CoV-2. APS patients from Peking Union Medical College Hospital during the COVID-19 outbreak (October-December 2022) were included. Age- and gender-matched APS patients without infection served as controls. Data on demographics, symptoms, treatments, and serum aPL levels were analyzed. Of 234 APS patients, 107 (45.7%) were infected with SARS-CoV-2. Typical symptoms included high fever (81.3%), cough/expectoration (70.1%), and pharyngalgia (52.3%). Age- and gender-based matching selected 97 patients in either infected or uninfected group. After infection, anti-β-2-glycoprotein I-IgG (aβ2GP1-IgG) increased from 4.14 to 4.18 AU/ml, aβ2GP1-IgM decreased from 9.85 to 7.38 AU/ml, and anticardiolipin-IgA (aCL-IgA) significantly increased with a median remaining at 2.50 APLU/ml. Lupus anticoagulants and other aPLs remained stable. Arterial thrombosis incidence increased from 18 (18.6%) to 21 (21.6%), while venous thrombosis incidence did not change. Additionally, 7 (6.5%) patients presented either new-onset or worsening thrombocytopenia, characterized by a significant decline in platelet count (no less than 10 × 10
Identifiants
pubmed: 38888664
doi: 10.1007/s10238-024-01400-5
pii: 10.1007/s10238-024-01400-5
doi:
Substances chimiques
Antibodies, Antiphospholipid
0
Antibodies, Anticardiolipin
0
beta 2-Glycoprotein I
0
Immunoglobulin G
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
130Subventions
Organisme : the Chinese National Key Technology R&D Program, Ministry of Science and Technology
ID : 2021YFC2501300
Organisme : Beijing Municipal Science & Technology Commission
ID : No.Z201100005520025
Organisme : CAMS Innovation Fund for Medical Sciences
ID : 2021-I2M-1-005
Organisme : National High Level Hospital Clinical Research Funding
ID : 2022-PUMCH-A-008, B-013, C-002
Informations de copyright
© 2024. The Author(s).
Références
Sammaritano LR. Antiphospholipid syndrome. Best Pract Res Clin Rheumatol. 2020;34(1): 101463.
doi: 10.1016/j.berh.2019.101463
pubmed: 31866276
Smatti MK, Cyprian FS, Nasrallah GK, Al Thani AA, Almishal RO, Yassine HM. Viruses and autoimmunity: a review on the potential interaction and molecular mechanisms. Viruses 2019;11(8).
Sundaresan B, Shirafkan F, Ripperger K, Rattay K. The role of viral infections in the onset of autoimmune diseases. Viruses 2023;15(3).
Kim B, Kaistha SD, Rouse BT. Viruses and autoimmunity. Autoimmunity. 2006;39(1):71–7.
doi: 10.1080/08916930500484708
pubmed: 16455584
Getts DR, Chastain EM, Terry RL, Miller SD. Virus infection, antiviral immunity, and autoimmunity. Immunol Rev. 2013;255(1):197–209.
doi: 10.1111/imr.12091
pubmed: 23947356
pmcid: 3971377
Fujinami RS, von Herrath MG, Christen U, Whitton JL. Molecular mimicry, bystander activation, or viral persistence: infections and autoimmune disease. Clin Microbiol Rev. 2006;19(1):80–94.
doi: 10.1128/CMR.19.1.80-94.2006
pubmed: 16418524
pmcid: 1360274
Ordi-Ros J, Villarreal J, Monegal F, Sauleda S, Esteban I, Vilardell M. Anticardiolipin antibodies in patients with chronic hepatitis C virus infection: characterization in relation to antiphospholipid syndrome. Clin Diagn Lab Immunol. 2000;7(2):241–4.
doi: 10.1128/CDLI.7.2.241-244.2000
pubmed: 10702499
pmcid: 95855
Prieto J, Yuste JR, Beloqui O, Civeira MP, Riezu JI, Aguirre B, Sangro B. Anticardiolipin antibodies in chronic hepatitis C: implication of hepatitis C virus as the cause of the antiphospholipid syndrome. Hepatology. 1996;23(2):199–204.
doi: 10.1002/hep.510230201
pubmed: 8591841
Bloom EJ, Abrams DI, Rodgers G. Lupus anticoagulant in the acquired immunodeficiency syndrome. JAMA. 1986;256(4):491–3.
doi: 10.1001/jama.1986.03380040065030
pubmed: 3088292
Canoso RT, Zon LI, Groopman JE. Anticardiolipin antibodies associated with HTLV-III infection. Br J Haematol. 1987;65(4):495–8.
doi: 10.1111/j.1365-2141.1987.tb04157.x
pubmed: 3580308
Abdel-Wahab N, Talathi S, Lopez-Olivo MA, Suarez-Almazor ME. Risk of developing antiphospholipid antibodies following viral infection: a systematic review and meta-analysis. Lupus. 2018;27(4):572–83.
doi: 10.1177/0961203317731532
pubmed: 28945149
Abdel-Wahab N, Lopez-Olivo MA, Pinto-Patarroyo GP, Suarez-Almazor ME. Systematic review of case reports of antiphospholipid syndrome following infection. Lupus. 2016;25(14):1520–31.
doi: 10.1177/0961203316640912
pubmed: 27060064
pmcid: 7508159
Jara LJ, Medina G, Saavedra MA. Autoimmune manifestations of infections. Curr Opin Rheumatol. 2018;30(4):373–9.
doi: 10.1097/BOR.0000000000000505
pubmed: 29528865
Bertin D, Brodovitch A, Beziane A, Hug S, Bouamri A, Mege JL, Heim X, Bardin N. Anticardiolipin IgG autoantibody level is an independent risk factor for COVID-19 severity. Arthritis Rheumatol. 2020;72(11):1953–5.
doi: 10.1002/art.41409
pubmed: 32564467
pmcid: 7323091
Yamazaki M, Asakura H, Kawamura Y, Ohka T, Endo M, Matsuda T. Transient lupus anticoagulant induced by Epstein-Barr virus infection. Blood Coagul Fibrinolysis. 1991;2(6):771–4.
doi: 10.1097/00001721-199112000-00012
pubmed: 1665993
Uthman I, Taher A, Khalil I. Hughes syndrome associated with varicella infection. Rheumatol Int. 2001;20(4):167–8.
doi: 10.1007/s002960000086
pubmed: 11411963
Labarca JA, Rabaggliati RM, Radrigan FJ, Rojas PP, Perez CM, Ferrés MV, Acuna GG, Bertin PA. Antiphospholipid syndrome associated with cytomegalovirus infection: case report and review. Clin Infect Dis. 1997;24(2):197–200.
doi: 10.1093/clinids/24.2.197
pubmed: 9114147
Asherson RA, Cervera R. Antiphospholipid antibodies and infections. Ann Rheum Dis. 2003;62(5):388–93.
doi: 10.1136/ard.62.5.388
pubmed: 12695147
pmcid: 1754545
Pamuk ON, Cakir N, Soy M, Aktoz M, Celik Y, Akdemir O. Mitral valve vegetation and cerebral emboli in a primary antiphospholipid syndrome patient who had hepatitis C virus infection: report of a case and review of the literature. Clin Rheumatol. 2003;22(2):136–9.
doi: 10.1007/s10067-002-0662-5
pubmed: 12740679
Stadler K, Masignani V, Eickmann M, Becker S, Abrignani S, Klenk HD, Rappuoli R. SARS–beginning to understand a new virus. Nat Rev Microbiol. 2003;1(3):209–18.
doi: 10.1038/nrmicro775
pubmed: 15035025
pmcid: 7097337
Fleming D. Influenza pandemics and avian flu. BMJ. 2005;331(7524):1066–9.
doi: 10.1136/bmj.331.7524.1066
pubmed: 16269494
pmcid: 1283192
Callaway E, Ledford H, Viglione G, Watson T, Witze A. COVID and 2020: an extraordinary year for science. Nature. 2020;588(7839):550–2.
doi: 10.1038/d41586-020-03437-4
pubmed: 33318685
Devreese KMJ, de Groot PG, de Laat B, Erkan D, Favaloro EJ, Mackie I, Martinuzzo M, Ortel TL, Pengo V, Rand JH, et al. Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis: update of the guidelines for lupus anticoagulant detection and interpretation. J Thromb Haemost. 2020;18(11):2828–39.
doi: 10.1111/jth.15047
pubmed: 33462974
Hu C, Li S, Xie Z, You H, Jiang H, Shi Y, Qi W, Zhao J, Wang Q, Tian X, et al. Comparison of different test systems for the detection of antiphospholipid antibodies in a Chinese cohort. Front Immunol. 2021;12: 648881.
doi: 10.3389/fimmu.2021.648881
pubmed: 34276646
pmcid: 8283786
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.
doi: 10.1016/S0140-6736(20)30183-5
pubmed: 31986264
pmcid: 7159299
Zhu J, Zhong Z, Ji P, Li H, Li B, Pang J, Zhang J, Zhao C. Clinicopathological characteristics of 8697 patients with COVID-19 in China: a meta-analysis. Fam Med Community Health 2020;8(2).
Ramos-Casals M, Cervera R, Lagrutta M, Medina F, García-Carrasco M, de la Red G, Bové A, Ingelmo M, Font J. Clinical features related to antiphospholipid syndrome in patients with chronic viral infections (hepatitis C virus/HIV infection): description of 82 cases. Clin Infect Dis. 2004;38(7):1009–16.
doi: 10.1086/382537
pubmed: 15034835
Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, Mehra MR, Schuepbach RA, Ruschitzka F, Moch H. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395(10234):1417–8.
doi: 10.1016/S0140-6736(20)30937-5
pubmed: 32325026
pmcid: 7172722
Levi M, Thachil J, Iba T, Levy JH. Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet Haematol. 2020;7(6):e438–40.
doi: 10.1016/S2352-3026(20)30145-9
pubmed: 32407672
pmcid: 7213964
Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–20.
doi: 10.1056/NEJMoa2002032
pubmed: 32109013
Klok FA, Kruip M, van der Meer NJM, Arbous MS, Gommers D, Kant KM, Kaptein FHJ, van Paassen J, Stals MAM, Huisman MV, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145–7.
doi: 10.1016/j.thromres.2020.04.013
pubmed: 32291094
pmcid: 7146714
Zlatković-Švenda M, Ovuka M, Ogrič M, Čučnik S, Žigon P, Radivčev A, Zdravković M, Radunović G. Antiphospholipid antibodies and vascular thrombosis in patients with severe forms of COVID-19. Biomedicines 2023;11(12).
Serrano M, Espinosa G, Serrano A, Cervera R. COVID-19 and the antiphospholipid syndrome. Autoimmun Rev. 2022;21(12): 103206.
doi: 10.1016/j.autrev.2022.103206
pubmed: 36195247
pmcid: 9527199
Ott O, Herrmann E, Schulz A, Lindhoff-Last E. The APSANTICO study: a prospective observational study to evaluate antiphospholipid antibody profiles in patients with thromboembolic antiphospholipid syndrome (APS) after COVID-19 infection and/or vaccination. Int J Mol Sci 2023;24(6).
Qin L, Duan X, Dong JZ, Chang Y, Han Y, Li Y, Jiang W, Fan H, Hou X, Cao W, et al. The unreversible reduced but persistent activated NK and CD8(+) T cells in severe/critical COVID-19 during omicron pandemic in China. Emerg Microbes Infect. 2023;12(1):2208679.
doi: 10.1080/22221751.2023.2208679
pubmed: 37102227
pmcid: 10187090
Dalekos GN, Zachou K, Liaskos C. The antiphospholipid syndrome and infection. Curr Rheumatol Rep. 2001;3(4):277–85.
doi: 10.1007/s11926-001-0031-4
pubmed: 11470045
Mendoza-Pinto C, García-Carrasco M, Cervera R. Role of infectious diseases in the antiphospholipid syndrome (including its catastrophic variant). Curr Rheumatol Rep. 2018;20(10):62.
doi: 10.1007/s11926-018-0773-x
pubmed: 30123926
Datta PK, Liu F, Fischer T, Rappaport J, Qin X. SARS-CoV-2 pandemic and research gaps: understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy. Theranostics. 2020;10(16):7448–64.
doi: 10.7150/thno.48076
pubmed: 32642005
pmcid: 7330865
Iba T, Levy JH. Thrombosis and thrombocytopenia in COVID-19 and after COVID-19 vaccination. Trends Cardiovasc Med. 2022;32(5):249–56.
doi: 10.1016/j.tcm.2022.02.008
pubmed: 35202800
pmcid: 8861143
Zandman-Goddard G, Shoenfeld Y. HIV and autoimmunity. Autoimmun Rev. 2002;1(6):329–37.
doi: 10.1016/S1568-9972(02)00086-1
pubmed: 12848988